BACKGROUND: Redundant blood supply by angiogenesis is a great advantage for the continuous growth of solid tumors. However, with chemotherapy (ChT), it can be disadvantageous due to increased drug delivery. An objective, reproducible, and non-invasive method for evaluating tumor blood supply is offered by perfusion CT. METHODS: Fifty-five advanced esophageal cancers (95% squamous cell carcinomas) were evaluated for hemodynamic parameters, including blood flow (BF), blood volume (BV), and mean transit time (MTT) of primary tumor by perfusion CT scan. Forty-six underwent neoadjuvant therapy (36 ChT and 10 chemoradiotherapy (CRT)) as primary treatment of the cancer and 36 underwent esophagectomy. RESULTS: Clinicopathological parameters were not significantly associated with hemodynamic parameters, except for hematogenic metastasis, which was not frequent (seven patients), but significantly associated with high BF (P = 0.0165). High BF and low MTT correlated significantly with a good response by neoadjuvant therapies (P = 0.0004 and P = 0.0124), while BV did not. The patients with high BF more frequently underwent esophagectomy and displayed better prognosis than those with lower values, while neither BV nor MTT was associated with patient survival. CONCLUSIONS: Tumor BF by perfusion CT can partly predict the effect of ChT and CRT and survival. Further large cohort studies in homogeneous patient groups will reveal its clinical usefulness. (c) 2007 Wiley-Liss, Inc.
BACKGROUND: Redundant blood supply by angiogenesis is a great advantage for the continuous growth of solid tumors. However, with chemotherapy (ChT), it can be disadvantageous due to increased drug delivery. An objective, reproducible, and non-invasive method for evaluating tumor blood supply is offered by perfusion CT. METHODS: Fifty-five advanced esophageal cancers (95% squamous cell carcinomas) were evaluated for hemodynamic parameters, including blood flow (BF), blood volume (BV), and mean transit time (MTT) of primary tumor by perfusion CT scan. Forty-six underwent neoadjuvant therapy (36 ChT and 10 chemoradiotherapy (CRT)) as primary treatment of the cancer and 36 underwent esophagectomy. RESULTS: Clinicopathological parameters were not significantly associated with hemodynamic parameters, except for hematogenic metastasis, which was not frequent (seven patients), but significantly associated with high BF (P = 0.0165). High BF and low MTT correlated significantly with a good response by neoadjuvant therapies (P = 0.0004 and P = 0.0124), while BV did not. The patients with high BF more frequently underwent esophagectomy and displayed better prognosis than those with lower values, while neither BV nor MTT was associated with patient survival. CONCLUSIONS:Tumor BF by perfusion CT can partly predict the effect of ChT and CRT and survival. Further large cohort studies in homogeneous patient groups will reveal its clinical usefulness. (c) 2007 Wiley-Liss, Inc.
Authors: Chaan S Ng; Adam G Chandler; James C Yao; Delise H Herron; Ella F Anderson; Chusilp Charnsangavej; Brian P Hobbs Journal: J Comput Assist Tomogr Date: 2014 Jul-Aug Impact factor: 1.826
Authors: Chaan S Ng; Brian P Hobbs; Adam G Chandler; Ella F Anderson; Delise H Herron; Chusilp Charnsangavej; James Yao Journal: Radiology Date: 2013-10-28 Impact factor: 11.105
Authors: Sonia P Li; Andreas Makris; Andrew Gogbashian; Ian C Simcock; J James Stirling; Vicky Goh Journal: Eur Radiol Date: 2012-04-17 Impact factor: 5.315
Authors: Martin Lundsgaard Hansen; Eva Fallentin; Carsten Lauridsen; Ian Law; Birgitte Federspiel; Lene Bæksgaard; Lars Bo Svendsen; Michael Bachmann Nielsen Journal: PLoS One Date: 2014-05-20 Impact factor: 3.240
Authors: Elżbieta Łuczyńska; Sylwia Heinze-Paluchowska; Paweł Blecharz; Barbara Jereczek-Fossa; Giuseppe Petralia; Massimo Bellomi; Andrzej Stelmach Journal: Med Sci Monit Date: 2015-01-13